514 related articles for article (PubMed ID: 34373422)
1. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
2. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
4. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
Ishiguro A; Ogata D; Ohashi K; Hiki K; Yamakawa K; Jinnai S; Tsutsui K; Takahashi A; Namikawa K; Yamazaki N
Medicine (Baltimore); 2022 Sep; 101(35):e30398. PubMed ID: 36107581
[TBL] [Abstract][Full Text] [Related]
5. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
Daetwyler E; Zippelius A; Danioth S; Donath MY; Gut L
Front Immunol; 2023; 14():1248919. PubMed ID: 37965350
[TBL] [Abstract][Full Text] [Related]
7. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
[TBL] [Abstract][Full Text] [Related]
8. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
Seo JH; Lim T; Ham A; Kim YA; Lee M
Medicine (Baltimore); 2022 Sep; 101(35):e30456. PubMed ID: 36107574
[TBL] [Abstract][Full Text] [Related]
9. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment.
Hatayama S; Kodama S; Kawana Y; Otake S; Sato D; Horiuchi T; Takahashi K; Kaneko K; Imai J; Katagiri H
J Diabetes Investig; 2022 Aug; 13(8):1458-1460. PubMed ID: 35396830
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.
Cao Y; Afzal MZ; Shirai K
BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417242
[TBL] [Abstract][Full Text] [Related]
11. Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy. A case report.
Boswell L; Casals G; Blanco J; Jiménez A; Aya F; de Hollanda A; Halperin I; Arance AM; Mora M; Hanzu FA
J Diabetes Investig; 2021 Dec; 12(12):2263-2266. PubMed ID: 34048145
[TBL] [Abstract][Full Text] [Related]
12. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
Mae S; Kuriyama A; Tachibana H
J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance study.
Bastin M; Allouchery M; Sassier M; Rouby F; Eftekhari P; Lebrun-Vignes B; Andreelli F; Bihan K
Therapie; 2021; 76(6):695-703. PubMed ID: 33836905
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
15. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
Thapi S; Leiter A; Galsky M; Gallagher EJ
J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
[TBL] [Abstract][Full Text] [Related]
16. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report.
Kikuchi F; Saheki T; Imachi H; Kobayashi T; Fukunaga K; Ibata T; Sato S; Ban N; Lyu J; Japar S; Murao K
J Med Case Rep; 2021 Apr; 15(1):214. PubMed ID: 33892782
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
Kotwal A; Haddox C; Block M; Kudva YC
BMJ Open Diabetes Res Care; 2019; 7(1):e000591. PubMed ID: 30899528
[TBL] [Abstract][Full Text] [Related]
19. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]